EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis

Brian Lee, Ussama Ghumman, Lisa D Pedicone, Andres Gomez Aldana, Eric Lawitz

Clinical and Molecular Hepatology · 01.10.2025 · 31 (4) · 1167-1196

DOI: 10.3350/cmh.2025.0337 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2025. Verfasst von Brian Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Texas Liver Institute, San Antonio, TX, USA. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a spectrum of pathology involving fatty liver disease that may progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. The prevalence of MASLD and metabolic dysfunction-associated steatohepatitis (MASH) continues to increase, mirroring the rise in global prevalence of related comorbidities such as obesity and type 2 diabetes mellitus. Due to the alarming rise of these comorbidities, a greater proportion of the population is at risk for developing MASLD and MASH. As such, there has been a significant effort to develop effective therapies for MASLD and MASH. Recently, the U.S. Food and Drug Administration approved resmetirom, a selective thyroid hormone receptor-beta agonist, as the first treatment for patients with MASH. In India, the Drug Controller General of India approved saroglitazar, a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, for the treatment of MASLD. Currently, we have various drug classes, including liver-specific therapies, in Phase 3 development with even more agents earlier in the pipeline. This review will discuss prospective therapies in later stages of development such as thyroid hormone receptor-beta agonists, PPAR agonists, glucagon-like peptide-1 receptor agonists, fibroblast growth factor 21 agonists, and fatty acid synthase inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHumansPPAR alphaPPAR gammaPhenylpropionatesThyroid Hormone Receptors betaPropionatesChalcones

Stichwörter der Autor:innen

Drug development in MASHMASHMASH treatmentNASH

Substanzen

PPAR alphaPPAR gamma2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acidPhenylpropionatesThyroid Hormone Receptors betaPropionatesChalcones

Autor:innen und Institutionen

  • Texas Liver Institute, San Antonio, TX, USA.
  • University of Texas Health Science Center, San Antonio, TX, USA.
  • University of the Incarnate Word, San Antonio, TX, USA.

Zitieren

APA

Lee, B., Ghumman, U., Pedicone, L. D., Aldana, A. G., & Lawitz, E. (2025). Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis. Clinical and Molecular Hepatology, 31(4), 1167-1196. https://doi.org/10.3350/cmh.2025.0337

Vancouver

Lee B, Ghumman U, Pedicone LD, Aldana AG, Lawitz E. Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis. Clinical and Molecular Hepatology. 2025;31(4):1167-1196. doi:10.3350/cmh.2025.0337

BibTeX
@article{Lee2025,
  author = {Lee, Brian and Ghumman, Ussama and Pedicone, Lisa D and Aldana, Andres Gomez and Lawitz, Eric},
  title = {Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {4},
  pages = {1167--1196},
  doi = {10.3350/cmh.2025.0337}
}
Kostenlos starten →